Compare FIBK & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIBK | LGND |
|---|---|---|
| Founded | 1879 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 1997 | N/A |
| Metric | FIBK | LGND |
|---|---|---|
| Price | $37.76 | $297.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $35.63 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 1.1M | 297.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | ★ 34.25 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.25 |
| Revenue Next Year | $4.91 | $19.41 |
| P/E Ratio | ★ $62.49 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.60 | $131.67 |
| 52 Week High | $40.60 | $326.63 |
| Indicator | FIBK | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 50.82 |
| Support Level | $37.95 | $290.20 |
| Resistance Level | $39.23 | $326.63 |
| Average True Range (ATR) | 0.84 | 11.05 |
| MACD | -0.25 | -3.89 |
| Stochastic Oscillator | 16.50 | 13.07 |
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.